ARC Startup Portfolio
Gesher Trade is proud to be a partner of Israel Sheba Hospital, having signed a letter of intent with this important global institution that designates Gesher as a legitimate intermediary to generate strong collaborative ties with Brazilian companies and governments with the ARC (developer and accelerator arm of the main Israeli startups). It is for this purpose that Gesher Trade presents a catalog of products developed by ARC.
Throughout Sheba's 70-year legacy and history of innovation, the main objective has been to translate basic research into patient-centered clinical technologies, meet the needs of the real world and contribute to the accessibility and quality of the health system in general. Working as a mentor and design partner, ARC helps startups adapt their technologies and models to real-world needs and applications. Sheba collaborates closely with industry leaders to promote the commercialization of intellectual property in the hospital and works with innovative startups inside and outside Israel. Today, more than 50 startups work with Sheba, from diagnostic tests to digital health, telemedicine and smart medical devices.
Sheba ARC is the ideal innovation laboratory for entrepreneurs and startups. They are given access to Sheba's vast medical database, doctors, researchers, networks and access to funding opportunities to accelerate innovation. Each year, more than 30 innovation projects are launched from within Sheba's rich ecosystem. Sheba is a crucial partner in the industry as an initiator, catalyst and testing center for Israeli medical technologies and new drugs.
Sheba is home to 3,200 researchers, technicians and the laboratory if one quarter of all medical research in Israel is conducted. More than 750 clinical trials are carried out each year, Sheba is the main site for clinical trials in humans conducted by the Weizmann Institute, Universities in Tel Aviv and Bar-Ilan. In addition, Sheba originates approximately 20 biomedical patent applications per year through the Technology Transfer Office.
Big Data and Artificial Intelligence
Predictive analytics with AI technology
CLEW Medical provides real-time artificial intelligence analytics platforms designed to help providers make better informed clinical decisions, predicting life-threatening complications in various healthcare settings. The purpose of CLEW is to provide solutions that can improve results and safety, streamline patient care, ultimately reducing the cost of care. Originally developed and proven in the intensive care unit, CLEW will develop machine learning models that have the potential to optimize clinical resources and guide healthcare professionals in predicting patient deterioration in all treatment settings.
AI / ML digitally based products and solutions
The Data Science Group (DSG) is an independent global artificial intelligence (AI) center of excellence that offers a rapid application development platform for end-to-end AI-based solutions. In addition, DSG provides a solution for AI governance, AI version control, AI monitoring and AI performance management in research and production environments. DSG has more than six years of proven experience in the development of various machine and AI-based learning systems for global brands. DSG is a multidisciplinary group of more than 30 leading data science researchers and entrepreneurs with experience in various sectors in health, finance, cybernetics, retail and energy, developing and maintaining AI models from vision to production. DSG has successfully developed more than 60 AI-based products that have been deployed in production environments for a variety of companies, from startups to multinational corporations in a variety of domains, such as Fin-Tech, Med-Tech, High-tech, Ad-Tech, Industry 4.0 and more.
Digital Platform for Genetics Counseling and testing
Igentify ™ is the world's first Digital Genetic Counselor ™ and complete genomic solution. The company automates genetic counseling to collect, analyze, interpret and generate actionable results and reports, allowing precision medicine and access to genetic information that allows patients and healthcare professionals to make more informed decisions. Founded in 2016, the company raised $ 12 million and has offices in Haifa and New York. In January 2019, Igentify was selected by Deloitte as one of the Israeli start-ups at the forefront of the digital R&D revolution.
Data science and MLOps platform
The Iguazio Data Science Platform allows organizations to develop, deploy and manage artificial intelligence (AI) applications at scale. With Iguazio, data science and data engineering teams can run AI models in real time, deploy them anywhere (cloud, location or edge) and bring their most ambitious AI-based strategies to life. Medical centers and healthcare facilities like Sheba use Iguazio to solve the complexities of operationalizing machine learning for a multitude of real-time use cases, such as predicting the deterioration of the COVID-19 patient, assisting in real-time decision making during surgery and optimize logistics with intelligent mobility. Iguazio brings data science to life.
AI-based immune system mapping
Founded in 2019, Immunai's mission is to fully map the immune system to better detect, diagnose and treat diseases, promoting personalized medicine through a comprehensive understanding of the immune system. The team consists of specialists in genomics, machine learning, bioinformatics, immunology and software engineering, with headquarters in New York City and offices in San Francisco and Tel Aviv. The company recently raised $ 20 million in initial financing led by Viola Ventures and TLV Partners.
Healthcare Data Platform
MDClone is a technology and services company focused on unlocking health data and enabling exploration, discovery and collaboration to improve patient health. With MDClone, any user can ask and answer any question in real time. This dramatic paradigm shift is made possible by MDClone's unique technology to organize, access and protect the privacy of patient data, allowing healthcare professionals to turn ideas into actionable insights in rapid cycles. MDClone's technology includes innovative synthetic data publishing capabilities that further enhance the protection of patient privacy. In combating the COVID-19 pandemic, MDClone launched the Pandemic Response Package, which allows healthcare organizations to quickly understand and leverage their own data around the COVID-19 cycles and gives them the ability to compare and collaborate with healthcare systems. health around the world. Founded in 2016 in Israel, MDClone works with leading healthcare systems, payers and life sciences companies in the United States, Canada and Israel. To date, the company has raised more than $ 42 million and recently announced partnerships with the United States National Institute of Health and Thomas Jefferson University / Jefferson Healt
Computer Vision and Image Technologies
RTC Vision offers innovative and innovative technological solutions and services for computer vision and artificial intelligence. We have partnerships with companies to accommodate your most challenging technological requirements and offer a variety of services, from projects of various sizes to involvement in the stages of entrepreneurship, where we lead all technological aspects. We are specialized in machine learning and deep learning, 3D technologies, advanced image processing, medical images, visual inspection and robotics. At RTC Vision, we work with a wide range of industries, such as medical companies, defense, construction, private consumers and material manufacturers. Since its creation in 2005, RTC Vision has provided cutting edge solutions for its customers. We are proud of our team of highly qualified, insightful and well-informed specialists, with a history of academic excellence and decades of collective experience in the field. With this team of professional algorithm developers, code optimization specialists and software developers, RTC Vision has over the years acquired an impeccable reputation for innovative technology, as well as efficient and smooth applicability for real-world products. We enjoy cooperative, productive and long-term collaborations with our customers and partners, and we are committed to providing ideal solutions together with high-level service.
Next generation of standalone micromobility solutions
Seamless Vision is developing the next generation of multipurpose autonomous micromobility solutions. Our technology allows robotic platforms to navigate autonomously indoors and outdoors, as well as maneuver safely in densely human environments. In this strategic partnership with Sheba Medical Center and ARC, Seamless Vision focuses on transforming logistics management in the healthcare world with its artificial intelligence (AI) and autonomous navigation technology. Integrating data from various sensors (visual, handle, ultrasonic and GIS), our AI-powered system generates a clear image of the robot's surroundings and allows it to navigate in complex environments. Together with our advanced Operations Management, Fleet Control and Demand Management System, as well as a friendly user interface for requesting logistical tasks, we offer an end-to-end solution for efficient management of logistical tasks.
AI-based medical imaging solutions
Zebra Medical Vision was founded in 2014 with a mission to impact hundreds of millions of patient lives by teaching computers to read and diagnose medical imaging exams. Zebra Medical Vision's image analysis platform allows healthcare institutions to identify patients at risk for disease and offer improved preventive treatment pathways to enhance patient care. In a world where 4 billion people do not have access to specialized radiologists, where there is a growing and aging population and exhausted and retired radiologists, there is an urgent need to take advantage of existing image data. This is to quickly build artificial intelligence solutions that help doctors and patients. Zebra empowers radiologists and helps them with healthcare professionals to manage the ever-increasing workload without compromising the quality of care. The company is a market leader with six products released by the FDA and recently obtained its first release by the FDA in oncology. Fast Company Magazine recognized the company in its ranking of the “5 best AI and machine learning companies”. Zebra Medical Vision has raised $ 57 million in financing to date from investors, including Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, Dolby Ventures and the top AI researchers. Amnon Shashua and Richard Socher. In June, the company announced a partnership with Apollo, India's largest hospital group, to assist doctors in diagnosing COVID 19.
Precision Medicine
AI Powered Precision Oncology Platform
Founded in 2017, Nucleai helps pathologists around the world to cope with the growing workload by providing AI-based diagnostic solutions, reducing analysis time and the rate of misdiagnosis. The company has raised $ 13.5 million to date and recently completed a $ 6.5 million series A round, led by the Debiopharm Group. The company also announced a collaboration with the Swiss-based Debiopharm Group, in the discovery of a predictive biomarker for the response to drugs and in improving data from clinical trials involving cancer patients.
Surgery
Surgical Intelligence and Automation Technologies
Caresyntax supports doctors, quality managers and hospital executives to improve quality and reduce risks in the operating room. The company offers a technology and services platform that will provide actionable surgical data through a combination of internet of things and data analysis technologies. entered into a partnership with Vaica Medical to improve the offer of remote care with medication management resources for patients hospitalized at home. The company completed a $ 7 million series A round in April 2020, led by the Israeli fund Crescendo Venture Partners.
Telemedicine
Remote service automation platform
Datos Health is a provider of a hospital-level patient management platform designed to connect the source of medical care directly with the patient to improve quality of life. This solution is a reliable platform based on machine learning that allows you to safely monitor, detect, analyze and even predict changes in patient conditions. It also adapts to any data source or device, harnessing the potential of the data generated by the patient and allows you to intervene to successfully manage complex oncology, cardiology and other treatment protocols. Founded in 2015, Datos was one of the first startups to join ARC and initially worked with Sheba to develop its first product as an application to monitor cardiac patients remotely.
Virtualization in Medicine
Virtualization in Medicine
XRHealth is a leader in extended reality therapeutic applications, providing virtual reality and augmented reality solutions to the medical industry. XRHealth is the first certified extended reality medical company in the world to develop FDA and CE registered medical applications. The company provides unprecedented health technology that helps doctors better manage their patients' care through specialized solutions for extended reality technology and data analysis. XRHealth created the first virtual reality telehealth clinic. This solution, known as the VRHealth Platform, collects and examines user data using artificial intelligence and cloud computing algorithms to provide advanced data analysis in real time, enabling healthcare providers to enhance their users' health experiences. and payers. The company offers a variety of patent-pending solutions, ranging from rehabilitation services to cognitive assessment and training, to pain management. XRHealth currently works with Sheba Medical Center to target multiple sclerosis patients. The company also works with several world-renowned health care providers, hospitals and rehabilitation centers in the United States. Founded in 2016, XRHealth is headquartered in Boston, Massachusetts, and has offices in Tel Aviv, Israel. To date, the company has raised $ 12.98 million, completing a $ 7 million series A round in April 2020, led by Bridges Israel and with the participation of Flint Capital and 20/20 Healthcare Partners. The Israeli Innovation Authority awarded the company a $ 450,000 grant in May 2020 to combat COVID-19. The company recently launched a virtual reality telehealth support group for people isolated due to the coronavirus, where patients with similar illnesses can get support from each other and doctors associated with XRHealth telehealth clinics.
Covid-19
Virtual Intelligence Solutions
AnyVision is the world's leading developer of computer vision software based on artificial intelligence. The company's leading-edge recognition solutions are built to work on any sensor, with any resolution, and are proven to operate in real-time and real-world scenarios. AnyVision brings together more than 20 years of experience in the field of security and academic research with the best and brightest minds in artificial intelligence, deep learning and computer vision to create a safer and better tomorrow. Deployed in Sheba to combat COVID-19, AnyVision's contact tracking solution uses privacy-compatible facial recognition to identify individuals close to known COVID-19 carriers. Founded in Israel in 2015, the company has offices in the USA, United Kingdom, Singapore, Mexico and Brazil. To date, the company has raised $ 117 million and recently completed a $ 43 million series B round in September 2020.
Continuous contactless monitoring solutions
EarlySense ® is a global leader in continuous, contactless monitoring solutions for the healthcare industry. Used worldwide in hospitals and post-acute care facilities, the EarlySense system assists caregivers in the early detection of potential patient adverse events, including code blue events resulting from cardiac or respiratory arrest, patient falls, pressure ulcers, avoidable ICU transfers and hospital readmissions. The EarlySense system captures critical patient information, alerting caregivers to potentially adverse events from the start. Founded in 2004, the company has also partnered with leading global technology companies, including Hillrom, Philips, Welch Allyn, Macnica and Mitsui. EarlySense is based in Ramat Gan, Israel and Woburn, Massachusetts. The company raised $ 145 million.
Non-invasive COVID-19 detection device
Kidod Science & Technologies is a medical device company that develops and produces advanced medical diagnostic devices. Using the company's advanced technology and accumulated experience, the team developed an in vitro diagnostic device for the rapid identification of the SARS-CoV-2 virus, responsible for the COVID-19 disease. The device, called Virion Test ™, can detect up to 150 pg of polyamines in saliva, which the virus releases during replication. The analysis process takes about 30 seconds, and the return time between the collection of the saliva sample and the result is about 50 seconds, making the test very fast. With over 3400 tests performed and 99.9% specificity compared to the CT30 double RT-PCR test, Virion Test ™ demonstrated excellent accuracy. Sampling and operation are simple, requiring no specialized or qualified personnel. Safety is also guaranteed to the user, since there is no risk of infection during the operation of the device.
AI solution to control epidemic outbreaks
Thermoguard is a patent-pending artificial intelligence-based data analysis solution that helps control epidemic outbreaks. The system collects biological measurements, transmits the data to the cloud and produces street-level threat assessments and visualizations. This technology allows you to manage the situation in real time and identify an epidemic outbreak four days earlier than existing systems allow. The team is made up of former officers of elite Israeli intelligence technology units with extensive knowledge in artificial intelligence and specialists in infectious diseases at Sheba Medical Center, Israel's main hospital.
Sheba technology transfer office
Radiology on a single screen
A leader in artificial intelligence-driven health, Aidoc's solutions analyze medical images to provide the most comprehensive artificial intelligence offering in the field. Aidoc is used by radiologists worldwide, helping them to maximize their clinical performance and streamline patient care. Founded in 2016, the company is headquartered in Tel Aviv, Israel, and has offices in New York. Aidoc is currently deployed in more than 350 medical facilities in the United States and worldwide, including Yale New Haven Health, UT Southwestern, Lahey Clinic, LucidHealth, Cedars-Sinai and UC San Diego. The company has six FDA approved solutions and has won several awards, including Time's 50 most brilliant companies, the Forbes 30 under 30 award and the CB Insights Most Innovative Digital Health award. In 2019, Aidoc's pulmonary embolism solution won the Minnie Award for “Best New Radiology Software”. To date, the company has increased $ 57.5 million and recently completed a $ 20 million series B round led by Square Peg Capital, based in Melbourne, Australia, with the participation of Magma Ventures, TLV Partners, Emerge, Alpha Intelligence Capital and Maor Investments. In May 2020, Aidoc received FDA approval to use the company's algorithms to detect and prioritize incidental CT findings associated with COVID-19.
Eliminating Prescription Errors
MedAware is transforming patient safety through real-time, artificial intelligence-based decision support for physicians. Crowdsource's solution makes medical practice to identify and prevent medication errors, opioid addiction, adverse drug evolution events and contraindications, and other medication-related risks. MedAware improves patient safety in hospital and outpatient settings and significantly reduces avoidable risks and costs each day.
Decision support platform for the early detection of breast cancer
In 2019, nearly 2.2 million people were diagnosed with breast cancer. However, the death rate among those diagnosed with breast cancer has the potential to decrease by a third if detected and treated early. In a global context, this means that almost 400,000 lives can be saved each year. MICA AI Medical uses artificial intelligence and machine learning to develop a decision support platform for the area of early detection of breast cancer, bringing a holistic solution in collaboration with Sheba Medical Center and its ARC Innovation Center. Between 40 and 50 percent of women have dense breasts, which limits the use of regular mammography. Using a contrast agent and MICA's artificial intelligence algorithm, MICA supports radiologists' decision for dense breasts, with a focus on young women. The platform, called Denise (Dense Breast Innovative System), shows the new mammograms and the changes between them over time, using self-alignment and automatic comparison algorithms. With the platform, the Sheba Medical Center's Meirav Breast Center reduced the rate of unnecessary biopsies by 30%.
Recently, MICA received US $ 600 thousand from the “MAGNETON” program of the Israeli Innovation Authority to market the Denise module. The MICA team has extensive experience in leading startups in the medical and digital health fields, both private and public companies.
AI software for diagnosing pathogens using spectral technology
Virusight Diagnostic is an artificial intelligence software company that uses exclusive spectral analysis and acquisition technology for diagnosing pathogens. COVID-19 rapid tests, based on Newsight Imaging spectral technology, using a non-invasive oral rinse. The technology allows for an affordable and portable solution that delivers results in less than a second. The solution allows detecting the spectral signature of the subject's reaction to the virus, using Virusight's artificial intelligence and machine learning technology to differentiate between sick and healthy. The technology was proven with tests carried out on tropical viruses with blood serum, with an accuracy of 99%. A COVID-19 oral rinse module is currently undergoing a clinical trial pilot test and shows results with more than 95% accuracy. The solution is connected to the cloud, can update future virus mutations through firmware and improve artificial intelligence models over time.
Founded in 2020, Virusight Diagnostic is the result of a mutual collaboration between Sheba Medical Center and Newsight Imaging, an Israeli startup founded in 2016 that develops advanced CMOS image sensors for three-dimensional machine vision and spectral analysis applications.
Minimally invasive surgical device for the treatment of glaucoma
Sanoculis Ltd. is an ophthalmic medical device company that develops a surgical solution for the third and fourth glaucoma treatment lines. Its Minimally Invasive Microsclerostomy (MIMS) device and technique are currently in clinical studies in India and Israel.
Noninvasive magnetic therapy for dry eye disease
Epitech Mag develops an innovative and non-invasive medical device and method for the treatment of dry eye syndrome.
Real-time monitoring systems for thermal ablation
TechsoMed is an Israeli medical imaging software company created to transform the way solid cancers are visualized and removed from the body with the introduction of BioTrace ™. Tracking a unique biological response from the tissue, BioTrace is the only system powered by an algorithm that can visualize the tissue necrosis ablation zone as it forms and represents a Tissue Damage Map (TDM) on the standard ultrasound image. The damage map represents the total extent of the damage, as will be seen only 24 hours after the treatment, increasing the accuracy of the treatment, minimizing the damage to healthy tissue and maximizing the ablation of the target tissue. In addition to oncology (tumor ablation), BioTrace's extended clinical applications also include cardiology (cardiac arrhythmia) and pain control (radiofrequency neurotomy).
Converting liver cells to insulin-producing cells
Orgenesis is a company in the development stage with a new therapeutic approach in the treatment of diabetes. The company has developed a solution that corrects organ malfunctions with new functional tissues created from the patient's existing organs. Orgenesis employs a molecular and cellular approach aimed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called an autologous transplant of insulin-producing cells.
Ophthalmic examination technology
Spring BioMed Vision is a company that has developed innovative ways to use spectroscopy and spectral imaging in today's medical world.
Analysis of medical images for radiology
RADLogics develops an image analysis solution based on machine learning to deal with the huge increase in the volume and complexity of medical image data. AlphaPoint ™ acts as the ideal Virtual Resident ™, providing detection and characterization of intelligent, meticulous and rapid discoveries. Vendors upload image data to the cloud-based AlphaPoint software, and the information flows directly to popular reporting systems, such as Nuance PowerScribe360, and to any image archiving and communication system (PACS).
Regenerative cell therapy for kidney disease
KidneyCure employs stem cell and progenitor therapies to combat one of the fastest growing epidemics in the world, kidney disease. The company uses a new process to isolate, purify and expand candidate kidney-forming stem and progenitor cells found in allogeneic human or adult autologous fetal kidney tissue.
Antibodies to cancer stem cell receptors
TaGeza Biopharmaceuticals is developing unique antibodies against cancer stem cell receptors to treat cancer.
Application system for injectable therapies in the eye
Everads therapy is developing a revolutionary drug and cell delivery system to deliver injectable therapies to the back of the eye. Diseases of the posterior segment of the eye threaten vision and are difficult to treat, due to their chronic and recurrent nature. The Everads delivery system, which delivers medication to the back of the eye through the choroid's extravascular matrix, will be superior to intravitreal injections and other current techniques.
Prevention of premature birth
PregnanTech is developing a device to prevent premature birth and allow women with a healthy pregnancy to deliver at term. Obstetricians do not know how to prevent spontaneous and unplanned preterm delivery in women with a healthy pregnancy. Treatments such as medications, cervical cerclage and pessaries are unsuccessful.
Catheter-based heart valve therapies
Innovalve develops an intelligent transcatheter mitral valve replacement therapy with superior anchoring capabilities. This includes a single device suitable for a broader range of patients, a smaller profile device for transeptal administration, a simple implantation procedure for all operators, and better valve anchoring and sealing.
Transseptal left atrial appendage closure device
Append Medical develops the latest generation transcatheter left atrial appendage closure system to reduce the risk of stroke in patients with atrial fibrillation.
Development of protein-based drugs
Bio-XL is a pre-clinical drug development company that develops new drug entities based on licensed technologies, from the initial stage to the final clinical and commercial stage. Bio-XL especially develops an anti-cancer treatment based on the Klotho hormone.
Development of Drugs for Immuno-Oncology
4C Biomed is an R&D start-up specialized in the field of immunoncology. The company's goal is to identify targets and develop new and potent drugs that aim to control the patient's own immune system to fight cancer efficiently.
Ophthalmic medicine delivery
Eximore develops a non-invasive insertion that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other important eye diseases. Our main candidate product is the EXP-LP punctum plug, which is a new application system designed to ensure that patients with glaucoma and ocular hypertension receive their medications.
Speech therapy platform
TikTalk develops the next generation speech therapy platform, combining speech recognition technology, clinical research and a gaming platform. This medical innovation will present a virtual auxiliary set of tools for speech therapists, in order to guide children and adults through proven and widely accepted training protocols.
New somatostatin-based targeted therapy platform
Starget Pharma is developing somatostatin analogs as a platform for targeted diagnostics and drug administration using a carrier with specific affinity for cancer cells. Compared to normal tissue, somatostatin receptors are overexpressed in a variety of tumors, such as those in the pancreas, breast, colon, prostate, bone, brain, lung, skin and pituitary. Therefore, they can be used as molecular markers of cancer for targeted diagnoses and drug distribution.
Microbiome-based products for combined therapy with Immuno Oncology
Ella Therapeutics is developing a fecal microbiota transplant to treat metastatic cancer refractory to immunotherapy.
Remote chest physiotherapy system for effective airway clearance
Synchrony Medical is developing a vest to clear the airways for patients living with chronic lung diseases, such as cystic fibrosis, COPD and bronchiectasis. Effective airway clearance reduces the risk of respiratory infections, pulmonary exacerbations and costly hospitalizations. The Synchrony vest offers personalized respiratory physiotherapy at the patient's home as an alternative to intensive manual respiratory physiotherapy in a hospital setting. Synchrony Medical aims to reduce the medical team's contact time with high-risk patients and make high-quality respiratory physiotherapy more accessible, easier and safer.
Cancer-related fatigue medication
Omeop has developed a drug to reduce cancer-related fatigue in patients starting chemotherapy and radiation therapy. The drug has been clinically tested and proven at the Sheba Medical Center in collaboration with Technion - Israel Institute of Technology. The company has completed its pre-seed investment and is moving towards production, marketing and sales.
HD video encoders and decoders
XVTEC Ltd. is an Israeli R&D company that develops innovative real-time video streaming technology. It provides ultra-low latency, high quality and reliable professional live video solutions for video over IP (H.264 / 5), live streaming, distribution and video contribution. XVTEC products are used by leading Israeli and international companies in a variety of sectors, including medicine, simulation, transmission and more.
Tumor immune avoidance and drug resistance therapies
Purple Biotech Ltd. is a clinical internship company focused on advancing first-class therapies to overcome tumor immune evasion and drug resistance, to create long-lasting and successful treatments for people with cancer. Our oncology pipeline includes NT219, a small molecule that targets the new cancer drug resistance pathways IRS1 / 2 and STAT3, currently in a phase 1/2 clinical trial, and CM24, a monoclonal antibody that blocks CEACAM1, a new immunological checkpoint that offers immunological support to tumor evasion and survival through multiple pathways, currently in a phase 1/2 clinical study. Purple Biotech also owns Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis and hypertension pain, approved by the FDA for commercialization in the USA
Design, Development Manufacture of electromechanical components and systems
Singer Instruments & Control has been specializing in the design, development and manufacture of medical devices for over 40 years. It provides its customers with complete, ready-to-use solutions, from the design of proof-of-concept prototypes to the serial production of the final product. The company is ISO13485 certified and maintains an internal ISO Class 7 clean room. Singer handles a wide variety of projects, mainly focused on miniaturization, high precision, biocompatibility and intelligent systems for complex manipulation. She has gained extensive experience in several technological areas and medical fields, such as active / passive implantable devices (remotely loaded, suture replacement, etc ...), surgical tools, special needles and delivery tools (including biocompatible materials and shape memory alloys) , such as Nitinol), medical robotics and exclusive sensors, miniature biocompatible electromechanics (miniaturized motors and sensors), electronic pills and diagnostic tools.
ARC Triventures
Audio personalization based on hearing test
Founded in 2016, Tunefork is audio personalization technology software that offers an ideal hearing experience, which improves the quality of life for people with hearing loss and the elderly. Hearing loss is a disability that affects 1.3 billion people worldwide, making their daily lives a challenge. Many of them have difficulty using their smart devices, such as smartphones, laptops, smart speakers and more, all of which depend on the clarity of sound for efficient operation.
The Tunefork software solution allows the user to perform a simple and clinically accurate hearing test, featuring a characterization of the user's specific hearing condition. The test results, paired with sophisticated algorithms to adjust the frequencies, create an ideal personalized audio experience for the user, called a personalized Audio Profile. Tunefork can be integrated with any smart device with any operating system and optimize all audio content: calls, ringtones and alerts, TV shows, voice messages, music, video, GPS instructions, in-car infotainment, assistant response smart and more. The company was the winner of the 2018 Sanara Ventures $ 2 million health startups competition and Sanara Ventures, and the 2019 MassChallenge Israel startups competition.
TuneFork has raised $ 2.03 million to date and recently completed a $ 1.5 million seed round led by Triventures ARC, an early stage seed fund partnership between Sheba Medical Center and Triventures Venture Capital. Tunefork recently joined ARC and announced a pilot study at Sheba Medical Center.
Polypharmacy recommendation platform
FeelBetter is an innovative startup that develops a risk forecasting and cost saving tool for polypharmacy patients. Based on complaints and / or medical records, the company stratifies patients according to their corresponding risk score, suggests optimizing the medication regimen, and helps care managers to focus on the right patient. Founded in 2018, FeelBetter recently closed its seed round led by Triventures ARC and is also funded by the Israel Innovation Authority.
Data activation platform for sensitive data
Lynx.MD presents a new cloud-based platform that allows hospitals, pharmacists and medical technology organizations to safely use vast sets of multimodal data. For the first time in the industry, healthcare innovators will gain simplified access to rich real-world data sets through the Lynx.MD platform, enabling rapid development of artificial intelligence applications that improve the quality and cost of care. Founded in 2019, Lynx.MD raised $ 2.5 million in a seed round led by the Triventures ARC fund. The company was recently selected to be part of the third Intel Ignite group, a 12-week accelerator program created by Intel Corporation to promote and develop early-stage startups.
MEDX Xelerator
Selective Minimally Invasive Treatment of solid tumors
CAPS Medical TM has developed a solution that successfully uses atmospheric non-thermal plasma (NTAP TM) in a minimally invasive procedure to treat a wide range of solid tumors. The CAPS Medical solution overcomes the challenges of providing NTAP to internal organs, selectively destroying cancer cells without damaging surrounding healthy tissue. In the $ 100 billion cancer therapy market, the company's first area of focus is non-muscular invasive bladder cancer (NMIBC), of which 500,000 people suffer in the United States alone and which afflicts 80,000 new patients annually. CAPS plans to apply its solution to other types of cancer, including lung, liver, breast, gastrointestinal and others. CAPS Medical's solution can make a profound and necessary impact.
ML-based surveillance tool for hemodialysis patients
PatenSee has developed a surveillance tool, harnessing the power of multimodal imaging and machine learning, designed to predict asymptomatic stenosis in hemodialysis patients to prolong longevity and improve quality of life.